Fulcrum Therapeutics, Inc. (FULC)
Develops experimental medicines to treat rare genetic blood disorders like sickle cell disease.
$3.72-0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-45.5%
The outlook
FULC is trading near its 52-week lows and well below its moving averages, showing weak near-term momentum. Analyst coverage leans bullish with an average price target roughly 57% above the current price, though the stock's overall sentiment scores bearish. The disconnect between analyst targets and current price reflects elevated uncertainty about near-term direction.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +57% vs current price
Analyst price target
~12-month · 6 analysts$5.83average target+56.8% vs now
Now $3.72
Low $3.00High $18.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$247.9M
52-wk high
$15.74
52-wk low
$2.83
50-day avg
$4.32
200-day avg
$8.07
Trailing P/E
—